Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chris Naprawa Insider Profile
4 Followers
Chris Naprawa, Director at Khiron Life Sciences, holds 3.12M shares in Khiron Life Sciences (Ticker: KHRNF). Most recently, Chris Naprawa Bought $1,000,000 shares of Khiron Life Sciences on Jun 15, 2022 for an estimated value of 150.00K.
Profitable Transactions
1 out of 17 Profitable Transactions
Average Return
-46.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Chris Naprawa holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jul 24, 2018 - Jul 24, 2019
Return:+98.70%
The most profitable trade made by Chris Naprawa
Chris Naprawa's Trading History
List of latest transactions for each holding click on a transaction to see Chris Naprawa's performance on stock
You May Also Like
Chris Naprawa insider profile FAQ
What is the percentage of profitable transactions made by Chris Naprawa?
The percentage of profitable transactions made by Chris Naprawa is 6%.
What is the average return per transaction made by Chris Naprawa?
The average return per transaction made by Chris Naprawa is -46.70%.
What stocks does Chris Naprawa hold?
Chris Naprawa holds: KHRNF stocks.
What was Chris Naprawa’s latest transaction?
Chris Naprawa latest transaction was an Informative Buy of $150.00K.
What was Chris Naprawa's most profitable transaction?
Chris Naprawa’s most profitable transaction was an Informative Buy of KHRNF stock on July 24, 2018. The return on the trade was 98.70%.
What is Chris Naprawa's role in Khiron Life Sciences?
Chris Naprawa's role in Khiron Life Sciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.